Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2018

Pharma News, 2018

Dow Jones component Pfizer has no interest in acquiring Bristol-Myers Squiq
Dow Jones component Pfizer has no interest in acquiring Bristol-Myers Squiq
The report from Citigroup analyst Andrew Baum sent Bristol shares toppling 2.
GSK hands rare disease gene therapies over to Orchard
GSK hands rare disease gene therapies over to Orchard
Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies.
China to remove tariffs on imported cancer drugs from May 1: state media
China to remove tariffs on imported cancer drugs from May 1: state media
BEIJING (Reuters) - China will remove import tariffs on cancer drugs from May 1, state media reported on Thursday, citing a meeting of the State Council, or cabinet, chaired by Premier Li Keqi...
Researchers may have found new weapon to tackle the flu
Researchers may have found new weapon to tackle the flu
Washington.
Teva to shut Ashdod plant within year, with loss of 175 jobs
Teva to shut Ashdod plant within year, with loss of 175 jobs
Company statement follows on from December announcement that debt-ridden pharma giant will fire 14,000 workers worldwide over next two years, including some 1,750 in IsraelTeva Pharmaceuticals announc...
Alexion to Acquire Wilson Therapeutics
Alexion to Acquire Wilson Therapeutics
NEW HAVEN, Conn.
Epilepsy drugs increase people's risk of dementia by up to 60% by breaking down brain cells
Epilepsy drugs increase people's risk of dementia by up to 60% by breaking down brain cells
Epilepsy medications increase people's risk of dementia by up to 60 per cent, new research suggests.
FDA Pushes Elagolix PDUFA Date to Q3 APRIL 10, 2018
FDA Pushes Elagolix PDUFA Date to Q3 APRIL 10, 2018
The US Food and Drug Administration (FDA) has announced that it will require additional time to review AbbVie and Neurocrine Biosciences, Inc’s elagolix for pain related to endometriosis.
Upadacitinib Demonstrates Positive Rheumatoid Arthritis Results in SELECT-COMPARE Trial
Upadacitinib Demonstrates Positive Rheumatoid Arthritis Results in SELECT-COMPARE Trial
AbbVie announced positive top-line results from the phase 3 SELECT-COMPARE clinical trial where after 12 weeks, 15 mg, once daily, upadacitinib (formerly ABT-494) met primary endpoints of ACR2...
Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma
WILMINGTON, Del.
Novo Nordisk obtains exclusive worldwide licence to EpiDestiny's sickle cell disease programme
Novo Nordisk obtains exclusive worldwide licence to EpiDestiny's sickle cell disease programme
Bagsværd, Denmark, 5 April 2018 ­- Novo Nordisk and EpiDestiny today announced that Novo Nordisk has obtained an exclusive worldwide licence to EpiDestiny's sickle cell disease (SCD) pro...
Merck's Keytruda helps lung cancer patients live longer in trial
Merck's Keytruda helps lung cancer patients live longer in trial
(Reuters) - Merck & Co’s (MRK.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand